Bayer bids $2.4bn for Norway pharma firm
AFP - [email protected]
Published: 26 Nov, 2013 CET.
Updated: Tue 26 Nov 2013 11:00 CET
German pharmaceutical group Bayer has made a bid for its Norwegian partner and competitor Algeta, specialised in cancer treatments, for 1.8 billion euro ($2.4 billion), the Nordic company said on Tuesday.
In a statement to the Oslo Stock Exchange responding to recent media reports, Algeta said that Bayer had offered 336 kroner (40.7 euro, $55.2) per share. The company added that the acquisition price quoted in the media (306 kroner) was lower than the actual offer from the German group. The bid was 27 percent higher than the last closing price of Algeta (264,60 kroner). Algeta is specialised in radiotherapy treatments that use radium 223 and thorium 227 to destroy cancer cells while causing minimal damage to surrounding tissue. The company's leading product Xofigo -- a treatment for prostate cancer -- was approved for use in the US in May and is distributed in cooperation with Bayer.
Comments
See Also
In a statement to the Oslo Stock Exchange responding to recent media reports, Algeta said that Bayer had offered 336 kroner (40.7 euro, $55.2) per share.
The company added that the acquisition price quoted in the media (306 kroner) was lower than the actual offer from the German group.
The bid was 27 percent higher than the last closing price of Algeta (264,60 kroner).
Algeta is specialised in radiotherapy treatments that use radium 223 and thorium 227 to destroy cancer cells while causing minimal damage to surrounding tissue.
The company's leading product Xofigo -- a treatment for prostate cancer -- was approved for use in the US in May and is distributed in cooperation with Bayer.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.